Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12644325 | 0.98 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL46682 | 0.98 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| Trifluoroacetic Acid SCHEMBL27830007 | 0.90 | USP2 (0.43) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL7687 | 0.89 | TLR8 (0.48) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL6221438 | 0.89 | TLR8 (0.48) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL8242595 | 0.88 | USP2 (0.61) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL943825 | 0.87 | TLR8 (0.47) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL12264373 | 0.86 | TLR8 (0.47) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL29263655 | 0.86 | TLR8 (0.47) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL18751236 | 0.86 | TLR8 (0.47) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | USP2 1502/4885SMN1; SMN2 3132/4885CHRM2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.